Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | TYR | P14679 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.32 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19841044 | 0.87 | PRKCI (0.39) | PRKCIKDM4ETYR | |
| SCHEMBL17826653 | 0.75 | PRKCI (0.37) | PRKCIHSD17B1CA12GABRA1GABRB2 | |
| SCHEMBL12948358 | 0.72 | CHEK1 (0.42) | PRKCIHSD17B1CA12 | |
| SCHEMBL15782860 | 0.71 | CA12 (0.44) | PRKCIKDM4ECA12CA9 | |
| SCHEMBL21569591 | 0.70 | ALDH1A1 (0.37) | KDM4ETYRALOX15 | |
| SCHEMBL31265069 | 0.69 | ALDH1A1 (0.41) | KDM4EP2RX7 | |
| SCHEMBL4430691 | 0.69 | TYR (0.48) | KDM4ETYRRAB9AALOX15 | |
| SCHEMBL17826654 | 0.69 | KCNA3 (0.51) | PRKCIKDM4ECA12CA9 | |
| SCHEMBL16450052 | 0.67 | AURKA (0.41) | KDM4E | |
| SCHEMBL15782877 | 0.67 | KDM4E (0.38) | PRKCIKDM4ECA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10669244-B2 | Synthesis of tetracyclines and analogues thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2020-06-02 | — | — | US | disclosed |
| EP-3138831-A1 | SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF | President and Fellows of Harvard College (US) | 2017-03-08 | — | — | EP | disclosed |
| EP-1753713-B1 | SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF | HARVARD COLLEGE (US) | 2016-07-27 | — | — | EP | disclosed |
| US-9365493-B2 | Synthesis of tetracyclines and analogues thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-06-14 | — | — | US | disclosed |
| US-20140163238-A1 | SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140163238-A1 | SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF | TET1, TET3, MYC | PRKCI 2091/4885KDM4E 800/4885HSD17B1 1662/4885 |
| US-10669244-B2 | Synthesis of tetracyclines and analogues thereof | TET1, TET3, MYC | PRKCI 2091/4885KDM4E 800/4885HSD17B1 1662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.